These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38634707)

  • 1. Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors.
    Liu TT; Wang Q; Zhou Y; Ye B; Liu T; Yan L; Fan J; Xu J; Zhou Y; Xia Z; Deng X
    J Med Chem; 2024 May; 67(9):7620-7634. PubMed ID: 38634707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies.
    Liu Z; Jiang K; Liu Y; Li J; Huang S; Li P; Xu L; Xu X; Hu X; Zeng X; Huang Z; Zhou Y; Li J; Long K; Wang M
    J Med Chem; 2024 Aug; 67(15):12735-12759. PubMed ID: 39053006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
    Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
    Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
    Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
    Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
    Min A; Im SA; Jang H; Kim S; Lee M; Kim DK; Yang Y; Kim HJ; Lee KH; Kim JW; Kim TY; Oh DY; Brown J; Lau A; O'Connor MJ; Bang YJ
    Mol Cancer Ther; 2017 Apr; 16(4):566-577. PubMed ID: 28138034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
    Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
    Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
    Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ
    Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
    Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
    Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment.
    Huang L; Shao J; Lai W; Gu H; Yang J; Shi S; Wufoyrwoth S; Song Z; Zou Y; Xu Y; Zhu Q
    Eur J Med Chem; 2024 Mar; 267():116159. PubMed ID: 38325007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escin-induced DNA damage promotes escin-induced apoptosis in human colorectal cancer cells via p62 regulation of the ATM/γH2AX pathway.
    Wang Z; Chen Q; Li B; Xie JM; Yang XD; Zhao K; Wu Y; Ye ZY; Chen ZR; Qin ZH; Xing CG
    Acta Pharmacol Sin; 2018 Oct; 39(10):1645-1660. PubMed ID: 29849127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.
    Inoue A; Robinson FS; Minelli R; Tomihara H; Rizi BS; Rose JL; Kodama T; Srinivasan S; Harris AL; Zuniga AM; Mullinax RA; Ma X; Seth S; Daniele JR; Peoples MD; Loponte S; Akdemir KC; Khor TO; Feng N; Roszik J; Sobieski MM; Brunell D; Stephan C; Giuliani V; Deem AK; Shingu T; Deribe YL; Menter DG; Heffernan TP; Viale A; Bristow CA; Kopetz S; Draetta GF; Genovese G; Carugo A
    Gastroenterology; 2021 Jul; 161(1):196-210. PubMed ID: 33745946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
    Degorce SL; Barlaam B; Cadogan E; Dishington A; Ducray R; Glossop SC; Hassall LA; Lach F; Lau A; McGuire TM; Nowak T; Ouvry G; Pike KG; Thomason AG
    J Med Chem; 2016 Jul; 59(13):6281-92. PubMed ID: 27259031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Selective and Potent ATR Degrader for Exploration its Kinase-Independent Functions in Acute Myeloid Leukemia Cells.
    Wang Y; Wang R; Zhao Y; Cao S; Li C; Wu Y; Ma L; Liu Y; Yao Y; Jiao Y; Chen Y; Liu S; Zhang K; Wei M; Yang C; Yang G
    Angew Chem Int Ed Engl; 2024 Apr; 63(17):e202318568. PubMed ID: 38433368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells.
    Harata S; Suzuki T; Takahashi H; Hirokawa T; Kato A; Watanabe K; Yanagita T; Ushigome H; Shiga K; Ogawa R; Mitsui A; Kimura M; Matsuo Y; Takiguchi S
    Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36734271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
    Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    Ratz L; Brambillasca C; Bartke L; Huetzen MA; Goergens J; Leidecker O; Jachimowicz RD; van de Ven M; Proost N; Siteur B; de Korte-Grimmerink R; Bouwman P; Pulver EM; de Bruijn R; Isensee J; Hucho T; Pandey G; van Lohuizen M; Mallmann P; Reinhardt HC; Jonkers J; Puppe J
    Breast Cancer Res; 2022 Jun; 24(1):41. PubMed ID: 35715861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.